An observational study in Carotid Artery Stenosis, sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd. (part of Blue Sail Medical Co., Ltd.) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Carotid Stenosis with a site in China — 33 open to participants now, 37 under way, 1 of them phase 3. Carotid Stenosis · China.
Among the 71 studies in Carotid Stenosis with a site in China, this one is the 14th largest by planned enrollment of the 34 observational ones that give a count, is one of 8 that started in 2025, is one of 34 observational ones, reaches primary completion later than 25 of the 36 other live ones, and was the 55th registered.
369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.
Browse Carotid Stenosis studies →33 of the 71 studies in Carotid Stenosis with a site in China are open now. Recruiting first, the newest first:
The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital · Sites in China
Ages 30–80
Beijing Tiantan Hospital · Sites in China
Ages 18+
General Hospital of Shenyang Military Region · Sites in China
Ages 40+
Chinese PLA General Hospital · Sites in China
Ages 10–90
Beijing Anzhen Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 204 is above the median of 176 across 161 observational studies indexed under Carotid Stenosis.
Median enrollment 178 across the 37 interventional studies, 200 across the 34 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 71 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shanghai Bluesail Boyuan Medical Technology Co., Ltd., one of the names counted as Blue Sail Medical Co., Ltd.. Under that name alone:
Shanghai Bluesail Boyuan Medical Technology Co., Ltd. is the lead sponsor of 7 studies on the registry; 7 are open to participants now.
Blue Sail Medical Co., Ltd. has 2 studies filed under Carotid Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Carotid Stenosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07004673Ruijin Hospital18F FDG and 68Ga FAPI PET/MR Imaging of Carotid Artery Plaque Vulnerability: A Clinical Study in Carotid Artery Plaque Patients | 2026-12-31 |
| NCT05134246Xuanwu Hospital, BeijingCarotid Revascularization for Radiation Induced Carotid Artery Stenosis | 2026-12-31 |
| NCT07036991Changhai HospitalA Cohort Study Comparing PCSK9 Inhibitor Plus Statin With Statin Monotherapy for Carotid Artery Stenosis | 2027-06-01 |
| NCT07247864Beijing Anzhen HospitalBalloon Guide Catheter Combined With Filter Protection for Carotid Artery Stenting | 2027-09-01 |
| NCT07412249General Hospital of Shenyang Military RegionRemote Ischemic Conditioning Plus Stenting for Symptomatic Carotid Artery Stenosis | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 71 studies in Carotid Stenosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Purpose: To assess the long-term safety and efficacy of the intravascular lithotripsy system for pre-treatment of calcified carotid artery stenosis.
Design: Prospective, multicenter, single-arm study with an extended follow-up period.
Sample Size: 204 participants (based on the final number of cases enrolled in the registration trial).
Endpoints:
Primary: Surgical success rate (residual stenosis \<30% after stenting). Secondary: Target lesion re-narrowing rate, target lesion revascularization rate, MAE rate, ipsilateral stroke rate, and MACCE rate at 3 and 6 months postoperatively.
Follow-Up: Participants will be followed up at 3 months ±15 days and 6 months ±30 days postoperatively.
Inclusion criteria:
All patients participating in this extended follow-up period are sourced from the registered clinical trial.
Ethics and Consent: The trial will be conducted in accordance with the Helsinki Declaration and Chinese regulations. Informed consent will be obtained from all participants or their legal guardians.
Sponsor: Shanghai Lanfan Boyuan Medical Technology Co., Ltd. Principal Investigator: Professor Huo Xiaochuan, Beijing Anzhen Hospital.
### Detailed Description
This clinical trial evaluates the safety and long-term efficacy of a disposable neurovascular intravascular lithotripsy (IVL) catheter and intravascular lithotripsy treatment device for pre-treatment of calcified lesions in the extracranial segment of the carotid artery. The study is designed as a prospective, multicenter, single-arm trial (extended follow-up period).
#### Study Population:
All patients participating in this extended follow-up period are sourced from the registered clinical trial.(The registered clinical trial:Participants aged 18-80 years with symptomatic (≥50%) or asymptomatic (≥70%) calcified carotid artery stenosis confirmed by CT angiography (CTA) and digital subtraction angiography (DSA) are eligible. Patients who have failed conventional balloon dilation and are planned for carotid artery stenting (CAS) will be included.)
#### Follow-Up: Participants will be followed up at 3 months ±15 days and 6 months ±30 days postoperatively. Assessments will include clinical evaluations, imaging studies (CT angiography or carotid ultrasound), and recording of adverse events.
Endpoints:
Informed consent will be obtained from all participants or their legal guardians. The study will be conducted in accordance with the Helsinki Declaration and local regulatory requirements.
All patients participating in this extended follow-up period are sourced from the registered clinical trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients participating in this extended follow-up period are sourced from the registered clinical trial.
Exclusion criteria:
none
All patients participating in this extended follow-up period are sourced from the registered clinical trial.
Target lesion re-narrowing rate
Proportion of patients with ≥50% diameter stenosis at the target lesion, assessed by imaging at 3 and 6 months.
Time frame: at 3 months and 6 months postoperatively
Target lesion revascularization rate
Incidence of repeat revascularization procedures at the treated lesion, evaluated at 3 and 6 months.
Time frame: at 3 months and 6 months postoperatively
MAE (Major Adverse Events) rate
Rate of major adverse events (death, myocardial infarction, stroke) within 3 and 6 months.
Time frame: at 3 months and 6 months postoperatively
Ipsilateral stroke rate
Incidence of stroke on the treated side, confirmed by clinical and imaging studies at 3 and 6 months.
Time frame: at 3 months and 6 months postoperatively
MACCE (Major Adverse Cardio-Cerebrovascular Events) rate
Composite rate of death, stroke, myocardial infarction, and revascularization at 3 and 6 months.
Time frame: at 3 months and 6 months postoperatively
Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.
Of 87 observational studies under Carotid Stenosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 104. This study's planned 31 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Bluesail Boyuan Medical Technology Co., Ltd. →